Teligent Inc (TLGT) : First Light Asset Management scooped up 20,449 additional shares in Teligent Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,019,059 shares of Teligent Inc which is valued at $8,244,187.Teligent Inc makes up approximately 3.62% of First Light Asset Management’s portfolio.
Other Hedge Funds, Including , D. E. Shaw reduced its stake in TLGT by selling 90,716 shares or 85.62% in the most recent quarter. The Hedge Fund company now holds 15,242 shares of TLGT which is valued at $123,308. Sg Americas Securities sold out all of its stake in TLGT during the most recent quarter. The investment firm sold 13,068 shares of TLGT which is valued $107,811. Cadence Capital Management sold out all of its stake in TLGT during the most recent quarter. The investment firm sold 50,454 shares of TLGT which is valued $416,246.Burt Wealth Advisors boosted its stake in TLGT in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 1,500 shares of Teligent Inc which is valued at $12,510. Teligent Inc makes up approx 0.01% of Burt Wealth Advisors’s portfolio.
On the company’s financial health, Teligent Inc reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $-0.03. The company had revenue of $17.14 million for the quarter, compared to analysts expectations of $16.03 million. The company’s revenue was up 92.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.
Many Wall Street Analysts have commented on Teligent Inc. Raymond James Initiated Teligent Inc on Jun 23, 2016 to “Strong Buy”, Price Target of the shares are set at $11.
Teligent Inc. formerly IGI Laboratories Inc. is a specialty generic pharmaceutical company. The Company is engaged in the manufacture and development of topical pharmaceutical over-the-counter (OTC) and cosmetic products. The Company under its label sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company has two platforms for growth: developing manufacturing and marketing a range of generic pharmaceutical products under its label in topical injectable complex and ophthalmic dosage forms and managing its contract manufacturing and formulation services business. The Company’s contract manufacturing and development business includes two services: contract formulation and contract manufacturing. The Company’s products are used in a range of applications such as cosmetics and prescription treatment of conditions such as dermatitis psoriasis and eczema.